Alnylam pushes back on doubts about its heart-failure silencers after AstraZeneca setback
AstraZeneca disclosed that its ATTR-CM drug Wainua failed in trials, prompting some analysts to question the value of RNA-silencing medicines, which Alnylam is now defending.
The failed study of AstraZeneca's Wainua in transthyretin amyloid cardiomyopathy sparked speculation that drugs that silence disease-causing proteins may not add benefit when patients already receive stabilizer therapies. Critics suggested stabilizers could be the superior approach. Alnylam Pharmaceuticals responded by defending its own silencer products, emphasizing the relevance for its approved drug Amvuttra and its pipeline candidate nucresiran.
Why it matters
The debate influences investor confidence and treatment options for a serious heart condition.
In this story
